Eating Disorders & GLP-1 RAs

About this resource

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.

PDF Available ?Yes
Year2025

See also

Stepped System of Care - Punjabi

National Eating Disorders Collaboration (NEDC) ਨੇ ਦੋ ਦਹਾਕਿਆਂ ਦੇ ਸੈਕਟਰ ਅਤੇ ਆਪ ਕੀਤੇ ਅਨੁਭਵ ਵਿਚਕਾਰ ਬਣੀ ਸਹਿਮਤੀ ਅਤੇ ਸੇਵਾ ਵਿਕਾਸ…

Read more

Eating Disorder Safe principles

Read more

Eating Disorders Information and Support for Australians – Resource Review 

In recognition that body image and Eating Disorders are a pressing issue within the Australian community, the Commonwealth of Australia commissioned this report to be prepared by the Butterfly Foundation (“Butterfly”) on behalf of the National Eating Disorders Collaboration (NEDC).

Read more

Assessing the Influence of Caregiver Factors on the Delivery of Family-Based Therapy for Child and Adolescent Eating Disorders

Research Project: Assessing the Influence of Caregiver Factors on Family-Based Treatment (FBT) for Child and Adolescent Eating Disorders: Phase Three Measure Evaluation Aim of the Research: The research aims to create and test a new assessment measure to identify caregiver strengths and challenges so that appropriate supports may be offered.

Read more